Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2566 to 2580 of 7688 results

  1. Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer ID6339

    In development [GID-TA11432] Expected publication date: 02 July 2025

    Technology appraisal guidance
    In development

  2. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development [GID-TA11220] Expected publication date: 05 February 2025

    Technology appraisal guidance
    In development

  3. Epcoritamab for treating relapsed or refractory follicular lymphoma ID6338

    In development [GID-TA11385] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Biomarker tests to help diagnose preterm labour in women with intact membranes (DG33)

    Evidence-based recommendations on biomarker tests to help diagnose preterm labour in women with intact membranes. The tests are Actim Partus, PartoSure and the Rapid fetal fibronectin (fFN) 10Q Cassette Kit (at thresholds other than 50 nanograms/millilitre)

    Diagnostics guidance
    Published
    4 July 2018
    View recommendations

    Sections for DG33

  5. Obesity: prevention and lifestyle management (QS update)

    In development [GID-QS10184] Expected publication date: TBC

    Quality standard
    In development

  6. Obesity: clinical assessment and management (QS update)

    In development [GID-QS10183] Expected publication date: TBC

    Quality standard
    In development

  7. Cardiovascular risk assessment and lipid modification

    In development [GID-QS10187] Expected publication date: 23 July 2025

    Quality standard
    In development

  8. Ovarian cancer QS update

    In development [GID-QS10182] Expected publication date: 05 February 2025

    Quality standard
    In development

  9. Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347]

    In development [GID-TA11496] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  10. Digital platforms to support cardiac rehabilitation

    Awaiting development [GID-HTE10060] Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  11. Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 5 December 2024.

    Technology appraisal guidance
    In consultation

  12. Intravascular lithotripsy for calcified coronary arteries during percutaneous coronary intervention

    In development [GID-IPG10391] Expected publication date: 05 February 2025

    Interventional procedures guidance
    In development

  13. Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

    In development [GID-TA11096] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Targeted Muscle Reinnervation for refractory pain after limb amputation

    In development [GID-IPG10369] Expected publication date: 20 June 2025

    Interventional procedures guidance
    In development

  15. Transcatheter aortic valve implantation for native aortic valve regurgitation

    In development [GID-IPG10357] Expected publication date: 11 June 2025

    Interventional procedures guidance
    In development